Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma

Guan,Yawei; Song,Haiyan; Zhang,Guohui; Ai,Xing

doi:10.3892/or.2014.3221

Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma

Authors:
- Yawei Guan
- Haiyan Song
- Guohui Zhang
- Xing Ai
View Affiliations

Affiliations: Department of Urinary Surgery, Beijing Military Region General Hospital, Beijing 100700, P.R. China, Department of Blood Transfusion, The 309th Hospital of Chinese PLA, Beijing 100091, P.R. China
Published online on: May 29, 2014 https://doi.org/10.3892/or.2014.3221
Pages: 748-754

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Flotillin-1 (FLOT1) is known to have a role in tumorigenesis; however, the effect of FLOT1 on proliferation and recurrence of human transitional cell carcinoma (TCC) is unclear. Samples from 156 TCC patients and 142 patients undergoing open bladder surgery for indications other than TCC were used in the present study. FLOT1 protein expression was determined by immunohistochemistry and western blot analysis, and mRNA expression was detected by RT-PCR and real-time PCR. A FLOT1-expressing pcDEF3 vector was stably transfected into 4 TCC cell lines and FLOT1 expression was decreased by RNAi. Proliferative analysis of TCC cells was detected by the WST-1 assay and a xenograft model using BALB/C nude mice. The association between FLOT1 expression and TCC recurrence was also analyzed by adhesion, migration and invasion assays. FLOT1 expression in TCC was significantly overexpressed compared to normal urothelial tissue, and the level of FLOT1 expression was significantly correlated with tumor size, pathologic grade, clinical stage and recurrence. In addition, FLOT1 significantly increased the proliferative ability of TCC cells in vitro and in vivo. TCC cells with a high level of FLOT1 expression exhibited a higher level of adhesion, migration and invasion. FLOT1 expression was shown to be upregulated in human TCC. These findings suggest that FLOT1 plays an important role in the proliferation and recurrence of TCC and that silencing FLOT1 expression might be a novel therapeutic strategy.

View Figures

View References

1	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 279:289–293. 2009. View Article : Google Scholar
2	Jacobs BL, Lee CT and Montie JE: Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 60:244–272. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kumar V, Abbas AK and Fausto N: Pathologic Basis of Disease. 8th edition. Saunders Elsevier; Philadelephia, PA: pp. 976–980. 2010
4	Shariat SF, Karakiewicz PI, Palapattu GS, et al: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 176:2414–2422. 2006. View Article : Google Scholar : PubMed/NCBI
5	Morgan TM and Clark PE: Bladder cancer. Curr Opin Oncol. 22:242–249. 2010. View Article : Google Scholar
6	Patra SK: Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta. 1785:182–206. 2008.PubMed/NCBI
7	Patra SK and Bettuzzi S: Epigenetic DNA-methylation regulation of genes coding for lipid raft-associated components: A role for raft proteins in cell transformation and cancer progression (Review). Oncol Rep. 17:1279–1290. 2007.PubMed/NCBI
8	Lingwood D and Simons K: Lipid rafts as a membrane-organizing principle. Science. 327:46–50. 2010. View Article : Google Scholar : PubMed/NCBI
9	Jacobson K, Mouritsen OG and Anderson RG: Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol. 9:7–14. 2007. View Article : Google Scholar : PubMed/NCBI
10	Simons K and Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 1:31–39. 2000. View Article : Google Scholar
11	Mollinedo F, de la Iglesia-Vicente J, Gajate C, et al: Lipid raft-targeted therapy in multiple myeloma. Oncogene. 29:3748–3757. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hitosugi T, Sato M, Sasaki K and Umezawa Y: Lipid raft specific knockdown of SRC family kinase activity inhibits cell adhesion and cell cycle progression of breast cancer cells. Cancer Res. 67:8139–8148. 2007. View Article : Google Scholar : PubMed/NCBI
13	Lang DM, Lommel S, Jung M, Ankerhold R and Petrausch B: Identification of reggie-1 and reggie-2 as plasmamembrane-associated proteins which cocluster with activated GPI-anchored cell adhesion molecules in non-caveolar micropatches in neurons. J Neurobiol. 37:502–523. 1998. View Article : Google Scholar
14	Stuermer CA, Lang DM, Kirsch F, Wiechers M, Deininger SO and Plattner H: Glycosylphosphatidyl inositol-anchored proteins and fyn kinase assemble in noncaveolar plasma membrane microdomains defined by reggie-1 and -2. Mol Biol Cell. 12:3031–3045. 2001. View Article : Google Scholar : PubMed/NCBI
15	Schulte T, Paschke KA, Laessing U, Lottspeich F and Stuermer CA: Reggie-1 and reggie-2, two cell surface proteins expressed by retinal ganglion cells during axon regeneration. Development. 124:577–587. 1997.PubMed/NCBI
16	Banning A, Tomasovic A and Tikkanen R: Functional aspects of membrane association of reggie/flotillin proteins. Curr Protein Pept Sci. 12:725–735. 2011. View Article : Google Scholar : PubMed/NCBI
17	Riento K, Frick M, Schafer I and Nichols BJ: Endocytosis of flotillin-1 and flotillin-2 is regulated by Fyn kinase. J Cell Sci. 122:912–918. 2009. View Article : Google Scholar : PubMed/NCBI
18	Baumann CA, Ribon V, Kanzaki M, et al: CAP defines a second signaling pathway required for insulin-stimulated glucose transport. Nature. 407:202–207. 2000. View Article : Google Scholar : PubMed/NCBI
19	Lin C, Wu Z, Lin X, et al: Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res. 17:3089–3099. 2011. View Article : Google Scholar : PubMed/NCBI
20	Hazarika P, McCarty MF, Prieto VG, et al: Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 64:7361–7369. 2004. View Article : Google Scholar : PubMed/NCBI
21	Thorn CC, Freeman TC, Scott N, Guillou PJ and Jayne DG: Laser microdissection expression profiling of marginal edges of colorectal tumours reveals evidence of increased lactate metabolism in the aggressive phenotype. Gut. 58:404–412. 2009. View Article : Google Scholar
22	Song L, Gong H, Lin C, et al: Flotillin-1 promotes tumor necrosis factor-α receptor signaling and activation of NF-κB in esophageal squamous cell carcinoma cells. Gastroenterology. 143:995–1005.e12. 2012.PubMed/NCBI
23	Santamaria A, Castellanos E, Gomez V, et al: PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts. Mol Cell Biol. 25:1900–1911. 2005. View Article : Google Scholar : PubMed/NCBI
24	Gomez V, Sese M, Santamara A, et al: Regulation of aurora B kinase by the lipid raft protein flotillin-1. J Biol Chem. 285:20683–20690. 2010. View Article : Google Scholar : PubMed/NCBI
25	Sternlicht MD and Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Res Cell Dev Biol. 17:465–516. 2001.
26	Lerner SP: Bladder cancer clinical trials. Urol Oncol. 23:275–279. 2005. View Article : Google Scholar : PubMed/NCBI
27	Mitsumori K, Tsuchiya N, Habuchi T, et al: Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection. BJU Int. 94:317–321. 2004. View Article : Google Scholar
28	Brausi M, Collette L and Kurth K: Variability in the recurrence rate at first follow up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 41:523–531. 2002. View Article : Google Scholar : PubMed/NCBI
29	Sylvester RJ, Oosterlinck W and Van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a meta analysis of published results of randomized clinical trials. J Urol. 171:2186–2190. 2004. View Article : Google Scholar
30	Pust S, Klokk TI, Musa N, et al: Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene. 32:3443–3451. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zhang SH, Wang CJ, Shi L, et al: High expression of FLOT1 is associated with progression and poor prognosis in hepatocellular carcinoma. PLoS One. 8:e647092013. View Article : Google Scholar : PubMed/NCBI
32	Ajili F, Darouiche A, Chebil M and Boubaker S: The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus calmette-guerin immunotherapy. Ultrastruct Pathol. 37:249–253. 2013. View Article : Google Scholar : PubMed/NCBI
33	Xu T, Zhu Z, Zhang X, et al: Predicting recurrence and progression in chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. Urology. 82:387–393. 2013. View Article : Google Scholar : PubMed/NCBI
34	Mares J, Szakacsova M, Soukup V, et al: Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results. Neoplasma. 60:295–301. 2013. View Article : Google Scholar : PubMed/NCBI
35	Hafner C, Knuechel R, Zanardo L, et al: Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 20:4910–4915. 2001. View Article : Google Scholar : PubMed/NCBI
36	Shang D, Liu Y, Yang P, et al: TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Urology. 79:966e1–966e7. 2012. View Article : Google Scholar : PubMed/NCBI